Stoke Therapeutics Inc (STOK)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.75B
Last updated: Nov 17, 2026 at 11:06 AM ET
Stoke Therapeutics Inc (STOK) Stock Forecast
Analysts expect Stoke Therapeutics (STOK) to earn -$4.01 per share in the fiscal year ending Dec 31, 2026, on revenue of $34.72M. Of 14 analysts, 14 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 2 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 14 ratings average 1.86, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 14.3% |
| Buy | 12 | 85.7% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 14
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss and revenue estimates rise 46.0%.
- Fiscal year ending Dec 31, 2026
- -$4.01
- EPS consensus, revenue $34.72M
- Fiscal year ending Dec 31, 2027
- -$4.09
- EPS consensus, revenue $50.69M
- Next report
- Mar 15, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$4.01 | -$4.29 to -$3.89 | 11 | $34.72M | $30.00M to $39.80M | 12 |
| Dec 31, 2027 | -$4.09 | -$5.00 to -$3.36 | 12 | $50.69M | $6.00M to $105.00M | 12 |
Quarterly Estimates
The EPS consensus rises from -$1.20 for the quarter ending Dec 31, 2026 to -$1.19 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$1.20 | -$1.31 to -$1.09 | 16 | $7.58M | $3.14M to $12.60M | 15 |
| Mar 31, 2027 | -$1.19 | -$1.43 to -$1.09 | 7 | $7.47M | $1.50M to $11.00M | 7 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 0 upward and 6 downward EPS revisions. Cuts outnumber raises in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 2 |
| Fiscal year ending Dec 31, 2027 | 0 | 3 |
| Quarter ending Mar 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$3.62.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$4.01 | -$3.62 | -$3.62 | -$3.62 | -$3.62 | N/A |
| Fiscal year ending Dec 31, 2027 | -$4.09 | -$3.53 | -$3.52 | -$3.52 | -$3.49 | N/A |
| Quarter ending Mar 31, 2027 | -$1.19 | -$0.98 | -$0.98 | -$0.98 | -$0.98 | N/A |
Frequently Asked Questions About STOK
What is the STOK stock forecast?
Consensus analyst estimates put Stoke Therapeutics's EPS at -$4.01 for the fiscal year ending Dec 31, 2026, on revenue of $34.72M. The consensus rating from 14 analysts is Buy.
How do analysts rate STOK stock?
Of 14 analysts covering Stoke Therapeutics, 2 rate it Strong Buy, 12 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from STOK next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$4.01, with estimates from -$4.29 to -$3.89 from 11 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$4.09, with estimates from -$5.00 to -$3.36 from 12 analysts.
What revenue do analysts expect from Stoke Therapeutics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $34.72M, with estimates from $30.00M to $39.80M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $50.69M, with estimates from $6.00M to $105.00M.
How many analysts cover STOK?
14 analysts rate Stoke Therapeutics stock, and 11 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
STOK pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors